- Home
- RMMZ vs TNYA Comparison
RMMZ vs TNYA Comparison
Compare RMMZ & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RMMZ
- TNYA
- Stock Information
- Founded
- RMMZ 2022
- TNYA 2016
- Country
- RMMZ United States
- TNYA United States
- Employees
- RMMZ N/A
- TNYA N/A
- Industry
- RMMZ Investment Managers
- TNYA Medicinal Chemicals and Botanical Products
- Sector
- RMMZ Finance
- TNYA Health Care
- Exchange
- RMMZ Nasdaq
- TNYA Nasdaq
- Market Cap
- RMMZ 122.3M
- TNYA 111.1M
- IPO Year
- RMMZ N/A
- TNYA 2021
- Fundamental
- Price
- RMMZ $13.96
- TNYA $0.83
- Analyst Decision
- RMMZ
- TNYA Strong Buy
- Analyst Count
- RMMZ 0
- TNYA 5
- Target Price
- RMMZ N/A
- TNYA $8.60
- AVG Volume (30 Days)
- RMMZ 25.6K
- TNYA 2.5M
- Earning Date
- RMMZ 01-01-0001
- TNYA 08-07-2025
- Dividend Yield
- RMMZ 7.33%
- TNYA N/A
- EPS Growth
- RMMZ N/A
- TNYA N/A
- EPS
- RMMZ 0.82
- TNYA N/A
- Revenue
- RMMZ N/A
- TNYA N/A
- Revenue This Year
- RMMZ N/A
- TNYA N/A
- Revenue Next Year
- RMMZ N/A
- TNYA N/A
- P/E Ratio
- RMMZ $19.41
- TNYA N/A
- Revenue Growth
- RMMZ N/A
- TNYA N/A
- 52 Week Low
- RMMZ $12.92
- TNYA $0.36
- 52 Week High
- RMMZ $16.99
- TNYA $4.06
- Technical
- Relative Strength Index (RSI)
- RMMZ 42.39
- TNYA 65.61
- Support Level
- RMMZ $14.09
- TNYA $0.79
- Resistance Level
- RMMZ $14.20
- TNYA $0.90
- Average True Range (ATR)
- RMMZ 0.09
- TNYA 0.07
- MACD
- RMMZ -0.01
- TNYA 0.01
- Stochastic Oscillator
- RMMZ 30.95
- TNYA 68.09
About RMMZ RiverNorth Managed Duration Municipal Income Fund II Inc.
RiverNorth Managed Duration Municipal Income Fund II Inc is a diversified, closed-end management investment company. The Fund's primary investment objective is current income exempt from regular U.S. federal income taxes. The Fund's secondary investment objective is total return.
About TNYA Tenaya Therapeutics Inc.
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration and precision medicine.